Table 3.

Clinical trials with CDK4/6 inhibitors in combination with IR

Cancer Type	Phase	Arm	n	Status	NCT
HGG a, DIPGb, bithalamic HGG	I/II	Ribociclib + IR	24	Active, not recruiting	NCT02607124
Glioma (HGG, DIPG et al.)	I	Ribociclib + Everolimus + IR	24	Recruiting	NCT03355794
Locally advanced HNSCC	I/II	Palbociclib + Cetuximab + IMRT c	33	Recruiting	NCT03024489
HPV-unrelated HNSCC	II	Palbociclib + Cetuximab or Cisplatin + IMRT	29	Recruiting	NCT03389477
Bone metastatic breast cancer (HR+/HER2-)	II	Palbociclib + Hormone therapy + IR	42	Recruiting	NCT03691493
Metastatic breast cancer (HR+/HER2-)	II	Palbociclib + Letrozole ± SBRT d	204	Not yet recruiting	NCT04220476

^a HGG, high-grade glioma

^b DIPG, diffuse intrinsic pontine glioma

^c IMRT, intensity-modulated radiation therapy

^d SBRT, stereotactic body radiation therapy